Next Biomedical Co.,Ltd. (KOSDAQ:389650)

Next Biomedical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Revenue	16,477	9,543	4,882	2,795	2,267
Other Revenue	-0	-	-	-0	-
Revenue	16,477	9,543	4,882	2,795	2,267
Revenue Growth (YoY)	72.67%	95.46%	74.67%	23.28%	0.29%
Cost of Revenue	5,028	3,787	2,813	2,618	2,998
Gross Profit	11,449	5,755	2,069	177.49	-731.09
Selling, General & Admin	4,465	2,610	2,407	2,246	2,866
Research & Development	7,581	6,622	4,783	3,579	3,245
Amortization of Goodwill & Intangibles	11.96	22.71	31.02	34.25	31.6
Other Operating Expenses	26.03	21.51	20.04	19.29	18.39
Operating Expenses	12,169	9,330	7,296	5,946	6,239
Operating Income	-719.54	-3,575	-5,226	-5,768	-6,970
Interest Expense	-367.31	-520.06	-574.37	-360.41	-1,413
Interest & Investment Income	926.51	634.82	574.31	200.41	138.66
Currency Exchange Gain (Loss)	-108.1	1,128	0.56	63.63	90.33
Other Non Operating Income (Expenses)	24.61	5,074	-2,429	268.61	-8,494
EBT Excluding Unusual Items	-243.82	2,742	-7,655	-5,596	-16,648
Gain (Loss) on Sale of Investments	-77.07	113.58	133.56	-102.48	-65.86
Gain (Loss) on Sale of Assets	9.81	4.24	-	5.29	69.58
Asset Writedown	-	-	-	-38.72	-0.8
Pretax Income	-311.08	2,860	-7,522	-5,732	-16,645
Net Income	-311.08	2,860	-7,522	-5,732	-16,645
Net Income to Common	-311.08	2,860	-7,522	-5,732	-16,645
Shares Outstanding (Basic)	8	7	6	6	5
Shares Outstanding (Diluted)	8	7	6	6	5
Shares Change (YoY)	13.65%	14.72%	1.10%	28.34%	13.05%
EPS (Basic)	-38.00	397.00	-1198.00	-923.00	-3440.00
EPS (Diluted)	-38.00	397.00	-1198.00	-923.00	-3440.00
Free Cash Flow	-1,902	-1,640	-4,225	-8,403	-6,101
Free Cash Flow Per Share	-232.28	-227.68	-672.87	-1353.18	-1260.87
Gross Margin	69.49%	60.31%	42.38%	6.35%	-32.25%
Operating Margin	-4.37%	-37.46%	-107.05%	-206.37%	-307.42%
Profit Margin	-1.89%	29.97%	-154.06%	-205.07%	-734.13%
Free Cash Flow Margin	-11.54%	-17.18%	-86.53%	-300.65%	-269.08%
EBITDA	-201.04	-3,082	-4,759	-5,305	-6,537
EBITDA Margin	-1.22%	-32.30%	-97.48%	-189.79%	-288.30%
D&A For EBITDA	518.51	492.36	467.32	463.41	433.53
EBIT	-719.54	-3,575	-5,226	-5,768	-6,970
EBIT Margin	-4.37%	-37.46%	-107.05%	-206.37%	-
Advertising Expenses	114.55	171.98	196.9	59.64	76.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.